Trial record 1 of 6 for:    Connect mm
Previous Study | Return to List | Next Study

Connect® MM- The Multiple Myeloma Disease Registry

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Celgene Corporation
Sponsor:
Information provided by (Responsible Party):
Celgene Corporation
ClinicalTrials.gov Identifier:
NCT01081028
First received: March 4, 2010
Last updated: December 31, 2013
Last verified: December 2013

March 4, 2010
December 31, 2013
September 2009
December 2023   (final data collection date for primary outcome measure)
Identify and summarize patterns in therapeutic regimens [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
Describe practice patterns of common first-line treatment regimens and subsequent therapeutic strategies in patients newly diagnosed with symptomatic MM in the community and academic setting
Same as current
Complete list of historical versions of study NCT01081028 on ClinicalTrials.gov Archive Site
  • Summarize Effectiveness of Treatment Regimens [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
    Describe any differences in effectiveness associated with different treatment regimens, including common first-line regimens, subsequent therapeutic strategies and regional effects (such as proximity of academic centers) in patients newly diagnosed with symptomatic MM
  • Summarize health-related quality of life (HRQoL) relation to treatment regimens/sequence and clinical outcomes [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
    Describe the health-related quality of life (HRQoL) of patients newly diagnosed with symptomatic MM, and to explore the association with HRQoL of treatment regimens/sequence and clinical outcomes
  • Clinical practice [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
    Provide insight into treatment regimens and therapy sequence in clinical practice as they relate to clinical outcomes (response, overall survival, progression-free survival) in patients newly diagnosed with symptomatic MM
  • Summarize Effectiveness of Treatment Regimens [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
    Describe any differences in effectiveness associated with different treatment regimens, including common first-line regimens, subsequent therapeutic strategies and regional effects (such as proximity of academic centers) in patients newly diagnosed with symptomatic MM
  • Summarize health-related quality of life (HRQoL) relation to treatment regimens/sequence and clinical outcomes [ Time Frame: up to 8 years ] [ Designated as safety issue: No ]
    Describe the health-related quality of life (HRQoL) of patients newly diagnosed with symptomatic MM, and to explore the association with HRQoL of treatment regimens/sequence and clinical outcomes
Not Provided
Not Provided
 
Connect® MM- The Multiple Myeloma Disease Registry
Connect® MM- The Multiple Myeloma Disease Registry

The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Patients with multiple myoloma and being treated in community or academic settings.

Multiple Myeloma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
3000
December 2023
December 2023   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Newly diagnosed with symptomatic MM within 2 months of enrollment in Connect® MM registry
  • Age ≥18 years
  • Willing and able to provide signed informed consent
  • Agrees to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel

Exclusion Criteria:

• Participation in a clinical study in which study treatment is blinded

Both
18 Years and older
No
Contact: Kristen Sullivan 1-913-266-0329 connectmm@celgene.com
United States,   Puerto Rico
 
NCT01081028
Connect ® MM
No
Celgene Corporation
Celgene Corporation
Not Provided
Study Director: Yasir Nagarwala, MD Celgene Corporation
Celgene Corporation
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP